Literature DB >> 30370132

Management of stage IA EGFR-mutant adenocarcinoma of the lung.

Robert Pirker1.   

Abstract

Entities:  

Year:  2018        PMID: 30370132      PMCID: PMC6186648          DOI: 10.21037/jtd.2018.08.70

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  7 in total

1.  How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.

Authors:  Yalei Zhang; Jianfei Shen; Charles B Simone; Federico Cappuzzo; Kwun M Fong; Rafael Rosell; Joe Y Chang; Luca Ampollini; J Isabelle Choi; Jianxing He; Tao Jiang
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

3.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

4.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

5.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

6.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

7.  Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.

Authors:  Anna Buder; Maximilian J Hochmair; Sophia Schwab; Tatjana Bundalo; Peter Schenk; Peter Errhalt; Romana E Mikes; Gudrun Absenger; Kurt Patocka; Bernhard Baumgartner; Ulrike Setinek; Otto C Burghuber; Helmut Prosch; Robert Pirker; Martin Filipits
Journal:  J Thorac Oncol       Date:  2018-03-02       Impact factor: 15.609

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.